Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 2Terminated 1Recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 5Breast 5Gynecologic 4Head & Neck 3Dermatologic 3Classical hematology 2Thoracic 1Sarcoma 1Myeloid 1Genitourinary 1Endocrine 1CNS 1

Conditions

Brain Neoplasms 362Glioblastoma 298Glioma 239Neuroblastoma 95Neoplasms 70Central Nervous System Neoplasms 62Astrocytoma 61Meningioma 59Breast Neoplasms 51Lung Neoplasms 46Carcinoma, Non-Small-Cell Lung 45Melanoma 39Sarcoma 34Medulloblastoma 33Meningeal Carcinomatosis 32Recurrence 31Neoplasm Metastasis 28Diffuse Intrinsic Pontine Glioma 28Prostatic Neoplasms 27Pheochromocytoma 26Paraganglioma 26Neurofibromatosis 1 26Pancreatic Neoplasms 24Ovarian Neoplasms 24Oligodendroglioma 22Ependymoma 21Head and Neck Neoplasms 20Spinal Cord Neoplasms 19Osteosarcoma 19Kidney Neoplasms 19

Interventions

Radiotherapy 1AZD1390 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Hereditary Sensory and Autonomic Neuropathies × CNS × Clear all
NCT03423628 2025-12-22

A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer

AstraZeneca

Phase 1 Recruiting
180 enrolled
CNS

Brain Neoplasms, Glioblastoma, Inhibition, Psychological, Meningeal Neoplasms, Hereditary Sensory and Autonomic Neuropathies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡